Maintelyte

Magnesium chloride hexahydrate, the active ingredient in Maintelyte, is an electrolyte solution presented as a sterile solution for injection for intravenous use. It helps maintain fluid balance and replace electrolytes in patients requiring volume resuscitation or electrolyte correction.

GNH USA supplies Maintelyte as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to EU quality standards and provides regulatory documentation, cold‑chain logistics where required, and ongoing technical support for clinical users.

Maintelyte is an intravenous electrolyte solution used to support fluid and electrolyte balance in clinical settings.

- Fluid and electrolyte maintenance: restores normal plasma volume and electrolyte concentrations in patients at risk of imbalance. - Electrolyte deficiency treatment: provides magnesium, potassium, sodium and chloride to correct documented deficiencies. - Volume resuscitation: supplies isotonic fluid for patients with dehydration, blood loss or shock. - Peri‑operative support: maintains electrolyte homeostasis during surgery or trauma care.

Adverse reactions may occur with any intravenous fluid. Monitoring during and after infusion is recommended.

Common Side Effects: - Infusion site irritation or pain. - Mild hypermagnesemia (elevated magnesium levels). - Mild hyperkalemia (elevated potassium levels). - Mild hypernatremia (elevated sodium levels). - Fluid overload leading to peripheral edema. - Transient increase in blood glucose.

Serious or Rare Side Effects: - Severe hypermagnesemia causing cardiac arrhythmia. - Severe hyperkalemia leading to life‑threatening arrhythmias. - Anaphylactic or severe allergic reaction. - Pulmonary edema from excessive volume administration. - Electrolyte imbalance requiring urgent correction. - Thrombophlebitis at the infusion site.

Maintelyte should be used with careful clinical assessment and monitoring. - Assess baseline electrolyte levels: obtain serum magnesium, potassium, sodium and glucose before infusion. - Monitor cardiac rhythm: continuous ECG monitoring is advised for patients at risk of arrhythmia. - Adjust infusion rate in renal impairment: reduce speed to avoid accumulation of electrolytes. - Avoid in known hypermagnesemia or hyperkalemia: contraindicated when serum levels are already elevated. - Use caution in heart failure: monitor for signs of fluid overload. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed before administering Maintelyte.

Major Interactions (Avoid): - Concurrent calcium gluconate infusion: risk of precipitation and reduced efficacy. - Co‑administration with other potassium‑containing IV solutions: may cause dangerous hyperkalemia. - Simultaneous magnesium sulfate infusion: risk of severe hypermagnesemia.

Moderate Interactions (Monitor Closely): - Loop diuretics: increase renal electrolyte loss, requiring closer monitoring. - ACE inhibitors or ARBs: may enhance potassium retention, necessitating serum checks. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can affect renal function and electrolyte handling.